DIFLORASONE DIACETATE CREAM IN AN OPTIMIZED VEHICLE VERSUS FLUOCINONIDE CREAM FOR THE TREATMENT OF PSORIASIS

The effectiveness and safety of diflorasone diacetate 0.05% in an opti mized cream vehicle (Psorcon Cream) and fluocinonide 0.05% cream (Lide x Cream) in the management of moderate-to-severe psoriasis was compare d in a double-blind multicenter 2-week study enrolling 100 patients, A randomized bilateral-paired comparison study design was used, The eff icacy results showed that the mean total scores (erythema, scaling, an d induration) were significantly lower for diflorasone diacetate-treat ed sites than for the comparable fluocinonide-treated sites at days 7 and 14 (P < 0.001), The comparative evaluations made by the investigat ors were also more favorable for diflorasone diacetate-treated sites t han for fluocinonide-treated sites at day 14 (P < 0.001), and the glob al evaluations of effectiveness done by the investigators favored the diflorasone diacetate-treated sites (P < 0.001), More patients rated t he improvement in their diflorasone diacetate-treated sites superior t o that in their fluocinonide-treated sites (59% vs 20%) at day 14 (P < 0.001), Patients also found diflorasone diacetate treatment to be mor e cosmetically acceptable than fluocinonide treatment (70% vs 44% rate d treatment as good to excellent), No adverse experiences were reporte d following diflorasone diacetate treatment, These findings demonstrat e that this cream formulation of diflorasone diacetate is an effective , well-tolerated, and cosmetically acceptable treatment for the manage ment of moderate-to-severe psoriasis.